Long-term follow-up of schistosomiasis serology post-treatment in Australian travelers and immigrants

J Travel Med. 2010 Mar-Apr;17(2):89-93. doi: 10.1111/j.1708-8305.2009.00379.x.

Abstract

Background: We undertook an observational follow-up study of schistosomiasis serology in both travelers and immigrants in a nonendemic country to determine the natural history of schistosomiasis antibody titer post-adequate treatment in those who have not been reexposed.

Methods: Longitudinal study of all adult travelers and immigrants presenting to the Royal Melbourne Hospital, Australia with positive schistosomiasis serology (titer >1: 64) between July 1995 and December 2005. All patients were treated with praziquantel and followed up clinically and serologically for a period up to 30 months.

Results: A total of 58 patients were included in the study including 26 travelers and 32 immigrants. Antibody titers often increased in the first 6 to 12 months post-treatment, especially in immigrants. After 30 months of post-treatment, 68% of travelers and 35% of immigrants (p < 0.01) achieved a fourfold antibody decline.

Conclusions: Schistosomiasis antibody titers varied after adequate treatment. Therefore an increase in titer in the first 6 to 12 months or a failure to reduce after 3 years should not automatically justify re-treatment.

MeSH terms

  • Adult
  • Anthelmintics / therapeutic use
  • Australia / epidemiology
  • Emigration and Immigration*
  • Female
  • Follow-Up Studies
  • Humans
  • Longitudinal Studies
  • Male
  • Praziquantel / therapeutic use
  • Schistosomiasis / blood
  • Schistosomiasis / drug therapy
  • Schistosomiasis / epidemiology*
  • Statistics, Nonparametric
  • Travel*
  • Treatment Outcome

Substances

  • Anthelmintics
  • Praziquantel